Midazolam Injection
Product Images NDC 0404-9780

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Midazolam (NDC 0404-9780). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula1.jpg (Formula1)

Chemical structure diagram of Midazolam hydrochloride, showing the molecular arrangement including chlorinated and fluorinated aromatic rings and nitrogen-containing heterocyclic rings.*

FDA Label Image

Formula2.jpg (Formula2)

Chemical structure diagram showing the interconversion between Midazolam and its open-ring form. The image depicts two molecular structures side by side, labeled as Midazolam and Open-ring Form, with a double-headed arrow indicating equilibrium between the two forms.*

FDA Label Image

Formula3.jpg (Formula3)

A line graph titled 'pH Dependence of Open-ring Form in Water' showing the percentage of open-ring form on the y-axis and pH on the x-axis ranging from 2.5 to 5.5. The graph depicts a steep decline in the percentage of open-ring form as pH increases, starting above 50% at pH 2.5, dropping to around 2% at pH 5.5.*

FDA Label Image

Image1.jpg (Image1)

A table listing adverse effects associated with Midazolam injection, including headache (1.3%) and local effects at the intramuscular injection site such as pain (3.7%), induration (0.5%), redness (0.5%), and muscle stiffness (0.3%).*

FDA Label Image

Image2.jpg (Image2)

A data table presenting adverse reactions associated with Midazolam injection, showing systemic side effects such as hiccoughs (3.9%), nausea (2.8%), vomiting (2.6%), coughing (1.3%), oversedation (1.6%), headache (1.5%), and drowsiness (1.2%), alongside local effects at the intravenous site including tenderness (5.6%), pain during injection (5.0%), redness (2.6%), induration (1.7%), and phlebitis (0.4%).*

FDA Label Image

Image3.jpg (Image3)

A data table titled "Observer's Assessment of Alertness/Sedation (OAA/S)" showing assessment categories including Responsiveness, Speech, Facial Expression, Eyes, and Composite Score with corresponding descriptions for scores from 5 (alert) to 1 (deep sleep). The table details behavioral and physical responses to assess sedation levels.*

FDA Label Image

Image4.jpg (Image4)

A data table showing frequency of observer’s assessment of alertness/sedation composite (OAA/S) scores in children aged 1 to 17 years undergoing procedures with intravenous Midazolam for sedation. The table lists age ranges, number of subjects (n), and corresponding counts and percentages for sedation scores ranging from 1 (deep sleep) to 5 (alert). It summarizes sedation assessment across four age categories and total subjects.*

FDA Label Image

Label1.jpg (Label1)

Midazolam 1 mg/mL injection vial label showing a 10 mL volume with 10 mg total. The label indicates use for intramuscular or intravenous injection, contains benzyl alcohol, and includes storage instructions at 20 to 25°C. The labeler is Henry Schein, Inc. with address at 80 Summit View Lane, Bastian, VA 24314. The NDC number 0404-9780-10 is displayed along with placeholders for lot number and expiration date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.